CD44 and glioblastoma: The binding of HA to its predominant receptor, CD44, was shown in vitro and in vivo to interact with MMPs [61], thereby driving tumour progression and upregulation of the PI3K/AKT and ERK signalling pathways, inducing pro-migratory effects and apoptotic resistance in GBM [62].